The world's first wiki where authorship really matters (Nature Genetics, 2008). Due credit and reputation for authors. Imagine a global collaborative knowledge base for original thoughts. Search thousands of articles and collaborate with scientists around the globe.

wikigene or wiki gene protein drug chemical gene disease author authorship tracking collaborative publishing evolutionary knowledge reputation system wiki2.0 global collaboration genes proteins drugs chemicals diseases compound
Hoffmann, R. A wiki for the life sciences where authorship matters. Nature Genetics (2008)

J.L. Schultze

Department of Adult Oncology

Dana-Farber Cancer Institute

Harvard Medical School




Name/email consistency: high



  • Department of Adult Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, USA. 1997 - 2001
  • Department of Adult Oncology, Disease Center for Hematologic Oncology, Dana-Farber Cancer Institute, Brigham and Women's Hospital, USA. 1999


  1. Tumour immunotherapy: new tools, new treatment modalities and new T-cell antigens. Schultze, J.L., Maecker, B., von Bergwelt-Baildon, M.S., Anderson, K.S., Vonderheide, R.H. Vox Sang. (2001) [Pubmed]
  2. A pilot study of combined immunotherapy with autologous adoptive tumour-specific T-cell transfer, vaccination with CD40-activated malignant B cells and interleukin 2. Schultze, J.L., Anderson, K.C., Gilleece, M.H., Gribben, J.G., Nadler, L.M. Br. J. Haematol. (2001) [Pubmed]
  3. From cancer genomics to cancer immunotherapy: toward second-generation tumor antigens. Schultze, J.L., Vonderheide, R.H. Trends Immunol. (2001) [Pubmed]
  4. Why do B cell lymphoma fail to elicit clinically sufficient T cell immune responses?. Schultze, J.L. Leuk. Lymphoma (1999) [Pubmed]
  5. T cell mediated immunotherapy for B cell lymphoma. Schultze, J.L., Nadler, L.M. J. Mol. Med. (1999) [Pubmed]
  6. An array of immunotherapeutic strategies for B-cell lymphomas. Schultze, J.L. Expert. Opin. Investig. Drugs (1999) [Pubmed]
  7. CD40-activated human B cells: an alternative source of highly efficient antigen presenting cells to generate autologous antigen-specific T cells for adoptive immunotherapy. Schultze, J.L., Michalak, S., Seamon, M.J., Dranoff, G., Jung, K., Daley, J., Delgado, J.C., Gribben, J.G., Nadler, L.M. J. Clin. Invest. (1997) [Pubmed]
  8. Vaccination as immunotherapy for B cell lymphoma. Schultze, J.L. Hematol. Oncol (1997) [Pubmed]
WikiGenes - Universities